Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial

Benjamin Diamond(Memorial Sloan Kettering Cancer Center), Ola Landgren(University of Miami Health System), Kylee Maclachlan(Memorial Sloan Kettering Cancer Center), Oscar Lahoud(Memorial Sloan Kettering Cancer Center), Malin Hultcrantz(United States Fish and Wildlife Service), Tim Peterson(Memorial Sloan Kettering Cancer Center), Gunjan L. Shah(Cornell University), Urvi A. Shah(United States Fish and Wildlife Service), Ahmet Doǧan(Memorial Sloan Kettering Cancer Center), Kazunori Murata(Memorial Sloan Kettering Cancer Center), Alexander M. Lesokhin(Memorial Sloan Kettering Cancer Center), Sydney X. Lu(Memorial Sloan Kettering Cancer Center), Sean M. Devlin(Memorial Sloan Kettering Cancer Center), Michael Scordo(Cornell University), Maria E. Arcila(Memorial Sloan Kettering Cancer Center), Lakshmi V. Ramanathan(Memorial Sloan Kettering Cancer Center), Even H Rustad(Memorial Sloan Kettering Cancer Center), David J. Chung(Memorial Sloan Kettering Cancer Center), Hani Hassoun(Memorial Sloan Kettering Cancer Center), Sham Mailankody(Memorial Sloan Kettering Cancer Center), Neha Korde(United States Fish and Wildlife Service), Sergio Giralt(Memorial Sloan Kettering Cancer Center), Katie Thoren(Sylvester Comprehensive Cancer Center), Mikhail Roshal(Memorial Sloan Kettering Cancer Center), Andriy Derkach(Memorial Sloan Kettering Cancer Center), Caleb Ho(Emergency Medicine Foundation), Carlyn Tan(United States Fish and Wildlife Service), Francesco Maura(Memorial Sloan Kettering Cancer Center), Eric L. Smith(Dana-Farber Cancer Institute), Heather Landau(Memorial Sloan Kettering Cancer Center)
The Lancet Haematology
May 25, 2021
Cited by 95


Related Papers